{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-197250","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.968659+00:00","generated_at":"2026-05-17T08:00:04.288548+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon reports new mouse-model data showing complete tumor regression and immune memory for ACR-368 and ACR-2316 combos","bullets":["Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.","Data supports rationale for front-line combination of ACR-368 and ACR-2316 with anti-PD(L)1 agents.","Pipeline update adds all-comer ACR-368 + ULDG ARM 3 of ongoing ACR-368-201 trial.","AP3 platform update highlights capability to generate actionable pathway insights for novel drug design."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-197250","json":"https://secwatch.observer/filing/0001193125-25-197250.json","markdown":"https://secwatch.observer/filing/0001193125-25-197250.md","text":"https://secwatch.observer/filing/0001193125-25-197250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/0001193125-25-197250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/acrv-20250905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:00:04.288548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}